I-GLIO (Integrated molecular characterization of glioma)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035921

Enrollment

450

Registered

2025-01-16

Start date

2022-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C71

Interventions

Group 1: Molecular charcterization of glioma for a better understanding of tumor heterogeneity.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with diagnosis of malignant glioma

Exclusion criteria

Exclusion criteria: Age < 18 years, withdrawal of informed consent.

Design outcomes

Primary

Measure	Time frame
Molecular charcterization of glioma for a better understanding of tumor heterogeneity	—

Secondary

Measure	Time frame
Integration of molecular results from blood, CSF and tissue and correlation with clinical and imaging data.	—

Countries

Germany

Contacts

Public ContactTobias Kessler

Universitätsklinikum Heidelberg

tobias.kessler@med.uni-heidelberg.de+49 6221 56 7504

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026